Bone and joint infections may be life threatening and result in crippling disability in survivors. The future promises new therapies for musculoskeletal infections, but also the emerging menace of antibiotic resistance. This issue explores advances and controversies in the management of osteomyelitis and septic arthritis, the challenge of methicillin-resistant Staphylococcus aureus (MRSA), antibiotic resistance in the management of gonococcal arthritis, the role of new drugs in the management of fungal bone and joint infection, and the latest in Lyme arthritis, reactive arthritis, viral arthritis, prosthetic joint infection, management of open fractures, musculoskeletal infections with multi-drug resistant tuberculosis, septic bursitis, tenosynovitis, and pyomyositis. This special issue will be of great interest to the widest medical audience, including general internists, infectious diseases physicians, orthopedic surgeons, sports physicians, rheumatologists, and pediatricians.